Skip to main content

Jaguar Health shares slump following Phase III Mytesi failure

Submitted by admin on
snippet

Jaguar Health said an initial analysis of anti-diarrhoeal drug Mytesi (crofelemer) in cancer patients showed the Phase III trial did not meet its primary endpoint.

Shares in the Nasdaq-listed company opened 66% lower compared to a pre-announcement market close. Jaguar has a market cap of $12m.

Source
Clinical Trials Arena

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Submitted by admin on
snippet

Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector.

Here are the key catalysts of the unfolding week.

Source
Yahoo/Benzinga